Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Although the main focus of immuno-oncology has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumour reduction and elimination. Tumour-associated macrophages often have net pro-tumour effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumours. Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumour-associated macrophages have had some success. We hypothesized that pharmacologic modulation of macrophage phenotype could produce an anti-tumour effect. We previously reported that a first-in-class selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro. Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumour microenvironment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes. TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumours. Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumour reduction. These data introduce class IIa HDAC inhibition as a means to harness the anti-tumour potential of macrophages to enhance cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylase inhibitor, TMP195, polarizes TAMs toward an anti‐tumor phenotype and increases the efficacy of carboplatin, paclitaxel, and anti‐PD‐1 therapies [84].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
The Immunological Genome Project: networks of gene expression in immune cells
The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864
Self-citation
Research works printed but not linked: 2
- DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL & Coussens LM Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery 1, 54– 67, 10.1158/2159-8274.cd-10-0028 (2011). 22039576 PMC3203524 · DOI · Paper page
- Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, Elpek KG, Chang SK, Knoblich K, Hemler ME, Brenner MB, Carroll MC, Mooney DJ, Turley SJ & Immunological Genome Project C Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature immunology 13, 499– 510, 10.1038/ni.2262 (2012). 22466668 PMC3366863 · DOI · Paper page
Cited by
Items 101–200 of 568
Zhai, K., Huang, Z., Huang, Q., Tao, W., Fang, X., Zhang, A., Li, X., Stark, G. R., Hamilton, T. A., & Bao, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00267-9 · Cited by 118
The emerging roles of macrophages in cancer metastasis and response to chemotherapy
Sanchez, L. R., Borriello, L., Entenberg, D. R., Condeelis, J. S., Oktay, M. H., & Karagiannis, G. S. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0218-056rr · Cited by 114
“…reprogramming, enhanced CD8+ T-cell activity, and restored the sensitivity of the tumors to the immune checkpoint inhibitors.145 In another approach, Guerriero et al. (2017) used a selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, capable of modulating monocyte responses to…”
MethodEpigenetic modifiers as new immunomodulatory therapies in solid tumours
Aspeslagh, S., Morel, D., Soria, J., & Postel-Vinay, S. C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy050 · Cited by 105
Xiong, A., Zhang, J., Chen, Y., Zhang, Y., & Yang, F. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104239 · Cited by 109
Tumor-associated macrophages: a short compendium
Prenen, H., & Mazzone, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2997-3 · Cited by 108
Cheng, H., Fan, X., Ye, E., Chen, H., Yang, J., Ke, L., You, M., Liu, M., Zhang, Y., Wu, Y., et al. (2021) · Advanced Materials · doi:10.1002/adma.202107674 · Cited by 104
Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad
Bleve, A., Durante, B., Sica, A., & Consonni, F. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165845 · Cited by 111
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)
Shen, S., & Kozikowski, A. P. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1708901 · Cited by 90
“Based on the successful story of TMP195 (developed by GSK), a selective Class IIa HDACi, the trifluoromethyloxadiazole has been shown to be a useful alternative ZBG to the hydroxamate group [115].”
BackgroundGupta, K. D., Shakespear, M. R., Curson, J. E. B., Murthy, A. M. V., Iyer, A., Hodson, M. P., Ramnath, D., Tillu, V. A., von Pein, J. B., Reid, R. C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.007 · Cited by 106
“Extended treatment with an inhibitor of class IIa HDAC enzymes reduced tumor burdens and metastasis in mouse breast cancer models, with these effects being linked to an immunostimulatory tumor-associated macrophage phenotype (Guerriero et al., 2017).”
InfluentialExploring tumor-associated macrophages in glioblastoma: from diversity to therapy
Zhao, W., Zhang, Z., Xie, M., Ding, F., Zheng, X., Sun, S., & Du, J. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00920-x · Cited by 130
“The unique advantage of this functional reprogramming strategy lies in its ability to enhance anti-tumor immune responses while preserving macrophage-mediated basic immune defense functions, potentially generating synergistic anti-tumor effects through activation of multiple immune cell types 152 .”
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Li, A., Chen, P., Leng, Y., & Kang, J. (2018) · Oncogene · doi:10.1038/s41388-018-0379-9 · Cited by 92
HDAC4 Controls Muscle Homeostasis through Deacetylation of Myosin Heavy Chain, PGC-1α, and Hsc70
Luo, L., Martin, S. C., Parkington, J., Cadena, S. M., Zhu, J., Ibebunjo, C., Summermatter, S., Londraville, N., Patora-Komisarska, K., Widler, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.023 · Cited by 90
The role of NLRP3 inflammasome in aging and age-related diseases
Liang, R., Qi, X., Cai, Q., Niu, L., Huang, X., Zhang, D., Ling, J., Wu, Y., Chen, Y., Yang, P., et al. (2024) · Immunity & Ageing · doi:10.1186/s12979-023-00395-z · Cited by 113
“Re-educated TAM to adopt a pro-inflammatory and anti-tumor phenotype shifts the originally pro-cancer inflammatory factors into anti-cancer agents, thereby suppressing cancer development [52, 53].”
BackgroundNovel tumor-associated macrophage populations and subpopulations by single cell RNA sequencing
Wang, J., Zhu, N., Su, L., Gao, Y., & Yang, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264774 · Cited by 112
“In addition, epigenetic regulators such as histone deacetylases could also modify macrophage phenotypes (160, 161).”
BackgroundBiology and therapeutic targeting of tumour‐associated macrophages
Beltraminelli, T., & De Palma, M. (2020) · The Journal of Pathology · doi:10.1002/path.5403 · Cited by 86
“In one study, epigenetic reprogramming of TAMs with the class IIa histone deacetylase (HDAC) inhibitor, TMP195, stimulated the differentiation of highly phagocytic and immunostimulatory macrophages in the MMTV-PyMT mammary tumour model [291].”
BackgroundCombined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer
Hu, Z. I., Ho, A. Y., & McArthur, H. L. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.029 · Cited by 90
Shen, S., Hadley, M. M., Ustinova, K., Pavlíček, J., Knox, T. J., Noonepalle, S. K. R., Tavares, M. T., Zimprich, C., Zhang, G., Robers, M. B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00946 · Cited by 86
Tong, N., He, Z., Ma, Y., Wang, Z., Huang, Z., Cao, H., Xu, L., Zou, Y., Wang, W., Yi, C., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.706286 · Cited by 99
Targeting tumor‐associated macrophages: A potential treatment for solid tumors
Chen, Y., Jin, H., Song, Y., Huang, T., Cao, J., Tang, Q., & Zou, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30139 · Cited by 82
“The PDL1 and PDL2 of TAMs induce T‐cell exhaustion and potentially limit the efficacy of T cells associated immunotherapies, and thus facilitating immune escape in solid tumors (Guerriero et al., 2017; Noman et al., 2014).”
BackgroundInfluentialSuarez‐Carmona, M., Williams, A., Schreiber, J., Hohmann, N., Prüfer, U., Krauß, J., Jäger, D., Frömming, A., Beyer, D., Eulberg, D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002505 · Cited by 87
Onkar, S., Cui, J., Zou, J., Cardello, C., Cillo, A. R., Uddin, M. R., Sagan, A., Joy, M., Osmanbeyoglu, H. U., Pogue–Geile, K. L., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00527-w · Cited by 96
Tumor-associated macrophages: role in tumorigenesis and immunotherapy implications
Zhu, S., Luo, Z., Li, X., Han, X., Shi, S., & Zhang, T. (2020) · Journal of Cancer · doi:10.7150/jca.49692 · Cited by 87
“macrophages can promote immunosuppression of TAMs in lung cancer, pancreatic cancer and melanoma models [88-91].”
BackgroundBelgiovine, C., Digifico, E., Anfray, C., Ummarino, A., & Torres, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103226 · Cited by 90
Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells
Yong, S., Chung, J. Y., Song, Y., Kim, J., Ra, S., & Kim, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119401 · Cited by 84
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Yam, C., Yen, E.-Y., Chang, J. T., Bassett, R. L., Alatrash, G., Garber, H. R., Huo, L., Yang, F., Philips, A. V., Ding, Q., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0144 · Cited by 78
“Interestingly, the finding that NAT-sensitive tumors have a higher T-cell to macrophage ratio compared with NAT-resistant tumors is consistent with preclinical studies showing that tumor-associated macrophages (TAM) mediate resistance to chemotherapeutic agents (33, 39, 40) and blocking macrophage recruitment pathways…”
ResultSelf-citationInnate and acquired immune surveillance in the postdissemination phase of metastasis
Gonzalez, H., Robles, I., & Werb, Z. (2018) · The FEBS Journal · doi:10.1111/febs.14325 · Cited by 77
Cellular metabolism of tumor‐associated macrophages – functional impact and consequences
Rabold, K., Netea, M. G., Adema, G. J., & Netea-Maier, R. T. (2017) · FEBS Letters · doi:10.1002/1873-3468.12771 · Cited by 89
“using Histone Acetyl Deacetylase (HDAC) inhibitors, which cause changes in the transcriptional profile of the macrophages and limits tumor growth [164, 165].”
Recent advances in class IIa histone deacetylases research
Asfaha, Y., Schrenk, C., Avelar, L. A. A., Hamacher, A., Pflieger, M., Kassack, M. U., & Kurz, T. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115087 · Cited by 78
Pharmacological targets of metabolism in disease: Opportunities from macrophages
Castegna, A., Gissi, R., Menga, A., Montopoli, M., Favia, M., Viola, A., & Canton, M. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107521 · Cited by 81
Macrophage diversity in cancer dissemination and metastasis
Mantovani, A., Marchesi, F., Mitri, D. D., & Garlanda, C. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01216-z · Cited by 108
“…mammary tumor model, combined treatment with chemotherapy or anti-PD-1 therapy with epigenetic reeducation of macrophages with histone deacetylase (HDAC) inhibitors resulted in macrophage reprogramming into proin fl ammatory and immunostimulatory effectors and increased antitumor effects [62].”
Immune oncology, immune responsiveness and the theory of everything
Turan, T., Kannan, D., Patel, M., Matthew Barnes, J., Tanlimco, S. G., Lu, R., Halliwill, K., Kongpachith, S., Kline, D. E., Hendrickx, W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0355-5 · Cited by 75
“The expression of these twenty representative genes is highly correlated with the extended ICR signature that includes approximately five-hundred transcripts and is representative of its main functional orientation as previously described [11, 12].”
BackgroundTumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression
Wang, R., Liu, Y., Liu, L., Chen, M., Wang, X., Yang, J., Gong, Y., Ding, B.-S., Wei, Y., & Wei, X. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.045 · Cited by 74
“Another therapeutic strategy is to enhance phagocytosis and immune-stimulatory of TAMs, like CD47/SIRPα antibody and class II HDAC inhibitor [33,34].”
BackgroundTumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy
Saeed, A. F. U. H. (2025) · Cells · doi:10.3390/cells14100741 · Cited by 112
“Inhibiting histone deacetylase (HDAC) may reprogram macrophage epigenetics and activate T cells for an immunological response [316,317].”
Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment
Haas, L., & Obenauf, A. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02746 · Cited by 89
“Indeed, in several studies using mouse models, depletion or re-education of TAMs using HDAC inhibitors or blockade of CSF-1 signaling, has shown synergism with checkpoint inhibition (90, 91).”
BackgroundLeblond, M. M., Zdimerova, H., Desponds, E., & Verdeil, G. (2021) · Cancers · doi:10.3390/cancers13184712 · Cited by 84
“In vitro and in vivo studies have reported that TMP195 reprograms M2-like macrophages toward M1-like macrophages, resulting in the reduction of tumor growth [124,195].”
BackgroundResultInfluentialLatest Advances in Targeting the Tumor Microenvironment for Tumor Suppression
Laplagne, C., Domagala, M., Le Naour, A., Quemerais, C., Hamel, D., Fournié, J.-J., Couderc, B., Bousquet, C., Ferrand, A., & Poupot, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194719 · Cited by 72
“Several synthetic molecules can also actively reverse the M2 phenotype of TAMs such as TMP195, an HDAC inhibitor, in breast cancer mouse models, or paclitaxel, an anti-microtubule agent, in patients with ovarian carcinoma [73,74].”
BackgroundTargeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
Xie, Y., Xie, F., Zhang, L., Zhou, X., Huang, J., Wang, F., Jin, J., Zhang, L., Zeng, L., & Zhou, F. (2021) · Advanced Science · doi:10.1002/advs.202101672 · Cited by 83
Beatson, R., Graham, R. A., Freile, F. G., Cozzetto, D., Kannambath, S., Pfeifer, E., Woodman, N. L., Owen, J., Nuamah, R. A., Mandel, U., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01359-5 · Cited by 77
Shen, J., Lyu, S., Xu, Y., Zhang, S., Li, L., Li, J., Mou, J., Xie, L., Tang, K., Wen, W., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.04.012 · Cited by 79
Ma, Z., Liu, D., Di, S., Zhang, Z., Li, W., Zhang, J., Xu, L., Guo, K. X., Zhu, Y., Li, X., et al. (2019) · Journal of Pineal Research · doi:10.1111/jpi.12587 · Cited by 70
Cotechini, T., Atallah, A., & Grossman, A. (2021) · Cells · doi:10.3390/cells10040960 · Cited by 82
A PGE2-MEF2A axis enables context-dependent control of inflammatory gene expression
Cilenti, F., Barbiera, G., Caronni, N., Iodice, D., Montaldo, E., Barresi, S., Lusito, E., Cuzzola, V., Vittoria, F. M., Mezzanzanica, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.016 · Cited by 77
Lavy, M., Gauttier, V., Poirier, N., Barillé‐Nion, S., & Blanquart, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702785 · Cited by 79
Wang, Y., Abrol, R., Mak, J. Y. W., Gupta, K. D., Ramnath, D., Karunakaran, D., Fairlie, D. P., & Sweet, M. J. (2022) · FEBS Journal · doi:10.1111/febs.16437 · Cited by 81
The unique immune microenvironment of liver metastases: Challenges and opportunities
Ciner, A., Jones, K. I., Muschel, R. J., & Brodt, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.003 · Cited by 79
Epigenetic modulation in cancer immunotherapy
Gallagher, S. J., Shklovskaya, E., & Hersey, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.006 · Cited by 73
Chimeric Antigen Receptor beyond CAR-T Cells
Qin, V. M., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2021) · Cancers · doi:10.3390/cancers13030404 · Cited by 72
“In contrast, M1 polarisation encompasses pro-inflammatory phenotype and harbours anti-tumour activity [71,72], thereby leading to great interest in engineering macrophages in cancer to assist immune surveillance.”
BackgroundFunctionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy
He, Y., Júnior, R. F. D. A., Cruz, L. J., & Eich, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101670 · Cited by 70
Emerging immunotherapies for metastasis
Edwards, S. C., Hoevenaar, W. H. M., & Coffelt, S. B. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01160-5 · Cited by 67
Wang, L., Hu, Y., Zhao, J., Huang, F., Liang, S.-Q., Dong, L., Chen, Y., Yu, H., Bai, J., Yang, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000517 · Cited by 68
Bhola, P. D., Ahmed, E., Guerriero, J. L., Sicińska, E., Su, E., Lavrova, E., Ni, J., Chipashvili, O., Hagan, T., Pioso, M. S., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aay1451 · Cited by 69
Self-citationRepolarizing macrophages improves breast cancer therapy
Cassetta, L., & Pollard, J. W. (2017) · Cell Research · doi:10.1038/cr.2017.63 · Cited by 64
New tools to prevent cancer growth and spread: a ‘Clever’ approach
Hollmén, M., Figueiredo, C. R., & Jalkanen, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0953-0 · Cited by 76
Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches
Conte, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108031 · Cited by 64
Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance
Long, K. B., Collier, A. I., & Beatty, G. L. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.12.003 · Cited by 65
“For example, inhibition of class IIa histone deacytelases (HDAC IIa) can induce macrophages with phagocytic and immunostimulatory properties capable of reducing tumor burden and suppressing metastasis in a spontaneous model of breast carcinoma (Guerriero et al., 2017).”
BackgroundMoreira, J. D., Koch, B. E. V., van Veen, S., Walburg, K. V., Vrieling, F., Guimarães, T. M. P. D., Meijer, A. H., Spaink, H. P., Ottenhoff, T. H. M., Haks, M. C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00036 · Cited by 66
“(26) in a similar monocyte differentiation model and was not toxic.”
BackgroundClass IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury
Zhang, W., Guan, Y., Bayliss, G. P., & Zhuang, S. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00405.2020 · Cited by 59
Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages
Li, X., Guo, X., Ling, J., Tang, Z., Huang, G., He, L., & Chen, T. (2021) · Nanoscale · doi:10.1039/d0nr08050k · Cited by 61
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
Frühauf, A., & Meyer‐Almes, F. (2021) · Molecules · doi:10.3390/molecules26175151 · Cited by 63
He, Y., Fang, Y., Zhang, M., Zhao, Y., Tu, B., Shi, M., Muhitdinov, B. I., Asrorov, A. M., Xu, Q., & Huang, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.022 · Cited by 60
The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy
Moran, B., Davern, M., Reynolds, J. V., Donlon, N. E., & Lysaght, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216121 · Cited by 64
Lin, Y., Jing, X., Chen, Z., Pan, X., Xu, D., Yu, X., Zhong, F., Zhao, L., Yang, C., Wang, B., et al. (2023) · Theranostics · doi:10.7150/thno.86928 · Cited by 68
Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy
Cortés‐Selva, D., Dasgupta, B., Singh, S., & Grewal, I. S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.004 · Cited by 66
Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer
Zhou, Q., Liang, J., Yang, T., Liu, J., Li, B., Li, Y., Fan, Z., Wang, W., Chen, W., Yuan, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114502 · Cited by 62
“Targeting PI3Kc and class IIa HDAC has been shown to transform TAM into M1 (Kaneda et al, 2016; Guerriero et al, 2017).”
BackgroundYue, W., Wu, S., Liu, Z., Niu, J., Zhou, Y., Ren, J., & Qu, X. (2022) · Materials Today · doi:10.1016/j.mattod.2022.01.024 · Cited by 60
Mezawa, Y., & Orimo, A. (2021) · FEBS Journal · doi:10.1111/febs.15851 · Cited by 61
Immuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 68
Turning enemies into allies—reprogramming tumor-associated macrophages for cancer therapy
Molgora, M., & Colonna, M. (2021) · Med · doi:10.1016/j.medj.2021.05.001 · Cited by 65
Luo, L., Yang, P., Mastoraki, S., Rao, X., Wang, Y., Kettner, N. M., Raghavendra, A. S., Tripathy, D., Damodaran, S., Hunt, K. K., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02226-9 · Cited by 70
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55
The HDAC2-SP1 Axis Orchestrates Protumor Macrophage Polarization
Zheng, X., Sarode, P., Weigert, A., Turkowski, K., Chelladurai, P., Günther, S., Kuenne, C. T., Winter, H., Stenzinger, A., Reu, S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1270 · Cited by 59
Crosstalk between gut microbiota and gut resident macrophages in inflammatory bowel disease
Zhang, H., Wang, X., Zhang, J., He, Y., Yang, X., Nie, Y., & Sun, L. (2023) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0123 · Cited by 63
“An overwhelming body of literature supports that these macrophages exert crucial roles in inflammation, [1] autoimmune diseases, [2] metabolic diseases, [3] cancers, [4,] and nervous system diseases.”
BackgroundAllavena, P., Anfray, C., Ummarino, A., & Torres, F. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1679 · Cited by 58
“The selective class IIa inhibitor, TMP195, stimulated the macrophage-mediated phagocytosis of tumor cells and TAM reprogramming into antitumor effectors in a mouse mammary model, showing better outcomes in combination with chemotherapy or anti-PD-1 (67).”
BackgroundMujal, A. M., Combes, A. J., Rao, A. A., Binnewies, M., Samad, B., Tsui, J., Boissonnas, A., Pollack, J. L., Argüello, R. J., Meng, M. V., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0588 · Cited by 60
Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle
Wattenberg, M. M., & Beatty, G. L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.002 · Cited by 59
Stott, A. J., Maillard, M. C., Beaumont, V., Allcock, D., Aziz, O., Borchers, A. H., Blackaby, W., Breccia, P., Creighton-Gutteridge, G., Haughan, A. F., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00532 · Cited by 55
Leveraging macrophages for cancer theranostics
Liu, L., Li, H., Wang, J., Zhang, J., Liang, X., Guo, W., & Gu, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114136 · Cited by 54
Luo, S., Yang, G., Ye, P., Cao, N., Chi, X., Yang, W., & Yan, X. (2022) · Biomolecules · doi:10.3390/biom12060850 · Cited by 62
Gong, J., Cheng, D., Liu, C., Wu, S., Sun, N., Zhao, L., Li, J., Xing, Y., & Zhao, J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202404184 · Cited by 53
O’Meara, T. A., Marczyk, M., Qing, T., Yaghoobi, V., Blenman, K., Cole, K. S., Pelekanou, V., Rimm, D. L., & Pusztai, L. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00350 · Cited by 59
“A recent study found that in a macrophage-dependent autochthonous mouse model of luminal B–type BC, inhibition of class IIa histone deacetylase (HDAC) by TMP195 induces the recruitment and differentiation of antitumor-type macrophages, reduces tumor burden and metastases, and enhances the durability of tumor reduction…”
ResultGlioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
Hu, J., Xiao, Q., Dong, M., Guo, D., Wu, X., & Wang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.593219 · Cited by 56
Kim, Y.-H., Wen, X., Bae, J. M., Kim, J. H., Cho, N., & Kang, G. H. (2018) · Histopathology · doi:10.1111/his.13674 · Cited by 66
“However, in murine mammary carcinoma, a selective class IIa histone deacetylation (HDAC) inhibitor has been used to modulate protumourous macrophage phenotype into an antitumour TAM that leads to reduced tumour burden, leaky vasculature, and lung metastasis.(22) This alternative approach with the HDAC inhibitor has al…”
MethodThe role of macrophages in the tumor microenvironment and tumor metabolism
Sadhukhan, P., & Seiwert, T. Y. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-023-00988-2 · Cited by 53
“In addition, certain HDAC inhibitors (histone deacetylase), e.g., TMP195, showed improved anti-tumor immunity and enhanced the efficacy of ICBs [182, 183].”
BackgroundTu, S., Xu, L., Qiu, J., Zhou, J., Wang, H., Hu, S., Yao, Y., Wang, Y., Deng, Y., Zhou, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650105 · Cited by 57
“TMP195, a IIa histone deacetylase antagonist, has been proven to alter macrophage polarization from a tumor-suppressive phenotype to a classical scavenger phenotype (94).”
BackgroundLü, Z., Mao, W., Yang, H., Santiago‐O’Farrill, J. M., Rask, P. J., Mondal, J., Chen, H., Ivan, C., Liu, X., Liu, C., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci146471 · Cited by 56
“Knockdown of class-IIa HDAC4/5 with siRNA prevented an ARN3236- or ARN326-mediated decrease of MEF2 promoter activity (Figure 7, C and D), but a decrease in MEF2 promoter activity was not prevented by inhibition of HDAC enzyme activity using TMP195, a selective class-IIa HDAC inhibitor (30) (Supplemental Figure 4D).”
Gong, T., Dong, Z., Fu, Y. S., Gong, T., Deng, L., & Zhang, Z. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01250h · Cited by 50
Mangiatordi, G. F., Intranuovo, F., Delre, P., Abatematteo, F. S., Abate, C., Niso, M., Creanza, T. M., Ancona, N., Stefanachi, A., & Contino, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01357 · Cited by 52
Luckhurst, C. A., Aziz, O., Beaumont, V., Bürli, R. W., Breccia, P., Maillard, M. C., Haughan, A. F., Lamers, M., Leonard, P., Matthews, K. L., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.009 · Cited by 47
Adipose tissue macrophages: implications for obesity-associated cancer
Li, B., Sun, S., Li, J.-J., Yuan, J.-P., Sun, S., & Wu, Q. (2023) · Military Medical Research · doi:10.1186/s40779-022-00437-5 · Cited by 64
“A selective inhibitor of IIa histone deacetylase polarizes macrophages into an antitumor phenotype that sensitizes the tumor to immune checkpoint blockade and chemotherapy in a T-celldependent manner [171].”
BackgroundZanganeh, S., Spitler, R., Hütter, G., Ho, J. Q., Pauliah, M., & Mahmoudi, M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0041 · Cited by 49
Tatárová, Z., Blumberg, D. C., Korkola, J. E., Heiser, L. M., Muschler, J. L., Schedin, P. S., Ahn, S. W., Mills, G. B., Coussens, L. M., Jonas, O. H., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01379-y · Cited by 55
“47,52 ), neuropilin-1 (refs.”
Xiao, L., Wang, Q., & Peng, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1157291 · Cited by 59
Chen, S., Zhang, P., Zhu, G., Wang, B., Cai, J., Song, L., Wan, J.-L., Yang, Y., Du, J.-X., Cai, Y., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01231-0 · Cited by 54
Yao, D., Li, C., Jiang, J., Huang, J. M., Wang, J., He, Z., & Zhang, J. C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112648 · Cited by 48
Epigenetics: An opportunity to shape innate and adaptive immune responses
Liotti, A., Ferrara, A. L., Loffredo, S., Galdiero, M. R., Varricchi, G., Rella, F. D., Maniscalco, G. T., Belardo, M., Vastano, R., Prencipe, R., et al. (2022) · Immunology · doi:10.1111/imm.13571 · Cited by 56
“Indeed, HDAC inhibitors modulate TAM phenotype and reduce the tumour burden in a murine model of breast cancer [36].”
BackgroundTREM1 activation of myeloid cells promotes antitumor immunity
Juric, V., Mayes, E., Binnewies, M., Lee, T., Canaday, P. S., Pollack, J. L., Rudolph, J. D., Du, X., Liu, V. M., Dash, S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add9990 · Cited by 50
“switch from an immunosuppressive to a proinflammatory myeloid phenotype could positively affect antitumor responses (7, 28, 36).”
BackgroundMetabolic reprogramming in type 2 diabetes and the development of breast cancer
Martin, S. D., & McGee, S. L. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0037 · Cited by 49
Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils
Russo, M., & Nastasi, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871513 · Cited by 48
Xu, Y., Li, P., Liu, Y., Xin, D., Lei, W., Liang, A., Han, W., & Qian, W. (2022) · 癌症:英文版 · doi:10.1002/cac2.12313 · Cited by 49
“The HDAC6 inhibitor, nexturastat A, reduces pro-tumorigenic M2 macrophages [92, 93], while class IIa HDACi improves phagocytic and immunostimulatory functions in macrophages, steering them toward an antitumor phenotype with enhanced capacity to activate cytotoxic T lymphocytes (CTLs) [94, 95].”
Background
Metadata
- Authors
- Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., Davis, S. P., Lobera, M., Nolan, M. A., & Letai, A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Nolan, Michael A.
- Letai, Anthony
- ORCID
- Venue
- Nature
- Published
- 2017-03
- Volume
- 543
- Issue
- 7645
- Pages
- 428-432
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8170529
- OpenAlex
- W2591627715
- Cited by
- 558
- References
- 35
- Citations by year
- 2026: 35 · 2025: 51 · 2024: 51 · 2023: 63 · 2022: 74 · 2021: 94 · 2020: 68 · 2019: 63 · 2018: 33 · 2017: 25
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA205967, F32CA180733)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- breast cancer, tumour-associated macrophages, antitumor immunity, tumor microenvironment, lung metastasis, chemotherapy synergy, T cell checkpoint blockade, CSF-1
- MeSH terms
- Animals, Benzamides, Breast Neoplasms, Cell Differentiation, Disease Models, Animal, Drug Synergism, Female, Humans, Lung Neoplasms, Macrophage Activation, Macrophages, Oxadiazoles, Phagocytosis, Cell Line, Tumor, Tumor Burden, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.